



bitBiome Closes USD 2.8 M USD in Oversubscribed Series B2 Round First Close Funding

bitBiome Inc. (Head office: Shinjuku-ku, Tokyo; Representative Director: Yuji Suzuki) announces that it has secured a US\$ 2.8 million investment in the first close of the Series B2 round.

The company's oversubscribed financing was raised from existing investors, University of Tokyo Edge Capital Partners Inc., Universal Materials Incubator Corporation, and three new investors, Agribusiness Investment & Consultation Co., Ltd., YOKOHAMA CAPITAL CO.,LTD. and The Seibu Shinkin Capital, Inc. joined this round. This brings bitBiome's cumulative fundraising to over US\$ 10 million.

Biomanufacturing is an initiative that aims to replace traditional manufacturing by producing chemicals such as bioplastics and materials, fuels, proteins and functional foods from biomass resources and atmospheric CO₂. The global biomanufacturing market is expected to continue to grow due to advances in technologies such as synthetic biology, AI, and robotics. As awareness of global environmental issues continues to increase, efforts to decarbonize, secure supply chains, and reduce dependence on fossil fuels will lead to the creation of new industries, with the market size expected to reach US\$ 30 trillion per year in the medium to long term.

In biomanufacturing, bitBiome is harnessing the power of 3.5 billion years of evolution by tapping into our proprietary database (bit-GEM), with over 1.2 billion sequences, built using our microbial single-cell sequencing platform (bit-MAP®). Utilizing the resources of our bit-GEM database, we provide custom enzyme discovery and engineering services using our dual in silico and in vitro platform (bit-QED).

bitBiome has conducted joint research agreements with various US and international companies from the pharmaceutical, food, chemical, and synthetic

biology industries and research institutes. In addition, bitBiome has a robust in-house R&D pipeline aimed to develop new enzyme solutions that focus on real-world needs.

The funds raised will be used to strengthen the platform technologies for internal research and development projects, including the development of proprietary enzymes to address environmental or healthcare issues. This investment will also allow bitBiome to expand its workforce and accelerate growth in the US and Japanese markets.

■About bitBiome, Inc.

bitBiome is a biotechnology company unlocking the full potential of our planet's microbes to power the future of the bioeconomy. bitBiome's platform is built on their proprietary single-cell microbial genome analysis technology, bit-MAP[®], which has enabled the creation of bit-GEM: an extensive and groundbreakingly diverse microbial database of over 1.3 billion sequences, sourced primarily from environmental samples and containing sequences not present in public databases. Leveraging their expertise in bioinformatics and machine learning, the company also offers a comprehensive enzyme discovery and engineering platform, bit-QED, which encompasses the identification, assessment, and modification of enzymes through wet lab evaluation and directed evolution. bitBiome is committed to improving existing biomanufacturing industries and creating new ones by delivering sequences and enzymes that cannot be found anywhere else. To learn more about bitBiome's platform and services, visit bitbiome.bio.

Contact: info@bitbiome.bio